Skip to Main Content
Contribute Try STAT+ Today

For the second time this month, Gilead Sciences (GILD) has lost a bid to invalidate patents owned by the U.S. government for using the Truvada pill to prevent HIV, which has been at the center of controversy over its cost and the extent to which taxpayer dollars funded key research.

The Patent Trial and Appeals Board ruled Gilead failed to demonstrate it was likely to win its argument for overturning two patents held by the Centers for Disease Control and Prevention, which helped fund academic work into HIV prevention that later formed the basis for the pill, also known as PrEP (here is one decision and here is the other). The board issued a similar ruling on Feb. 5 concerning challenges Gilead filed against two other CDC patents (see this and this).

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.